^
No biomarker
Anal Carcinoma
MIXE
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
TPF
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
FOLFCIS
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
mFOLFOX6
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Anal Carcinoma
DCF
Sensitive: A2 - Guideline
PD-L1 expression
Anal Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
CD163 expression
Anal Carcinoma
toripalimab
Sensitive: C3 – Early Trials
CD4 expression
Anal Carcinoma
toripalimab
Sensitive: C3 – Early Trials
PD-L1 expression
Anal Carcinoma
toripalimab
Sensitive: C3 – Early Trials
PD-L1 amplification + PD-L2 amplification + TMB-H
Anal Carcinoma
pembrolizumab
Sensitive: C4 – Case Studies